MTOR and neoplasm: There is evidence that VDC597 decreases PI3K-AKT-mTOR signaling activation and tumor growth in canine-derived OS cells both in vitro and in vivo, as well as increases cell death, decreases VEGF production, decreases cellular migration, and acts in an additive fashion with chemotherapeutic drugs in vitro.